Investigation of the safety and efficacy of Budesonide ( Zentacort Capsules ) in patients with Crohn's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224091

Enrollment

200

Registered

2018-10-11

Start date

2017-10-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

investigational material(s) Generic name etc : Budesonide ( Zentacort Capsules 3mg ) INN of investigational material : Budesonide Therapeutic category code : 239 Other agents affecting digestive organ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: mild to moderate active Crohn's disease in patients

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Adverse event, clinical laboratory tests, efficacy	—

Countries

Japan

Contacts

Public Contactpharmacovigilance Contact for

ZERIA Pharmaceutical Co., Ltd.

iyakujo@zeria.co.jp+81-3-3663-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026